Markets

Pasithea Therapeutics Presents Phase I Dose-Escalation Trial Of PAS-004 Inhibitor; Announces No Dose Limiting Toxicities Seen; No Participant Discontinued PAS-004; No Grade 3, Higher Observed

Oct 23, 2026 · 09:20 AM ET· updated 2h ago

Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced

Why It Matters

Pasithea tested a new medicine on people and nobody got really sick. When a medicine seems safe in early testing, that is usually good news for the company.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

KTTA0.41

-0.04 (-8.78%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.